Trial Profile
Comparison of THVD-201, a Combination of Tolterodine and a Muscarinic Agonist vs. Tolterodine Alone vs. Placebo to measure the tolerability in Subjects with Overactive Bladder (OAB) Symptoms (Protocol No.: THVD-201-002).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Tolterodine/pilocarpine (Primary) ; Tolterodine
- Indications Overactive bladder; Urge incontinence
- Focus Therapeutic Use
- 04 Apr 2013 Status changed from recruiting to completed according to a TheraVida media release.
- 02 Apr 2013 Results published in a TheraVida Media Release.
- 19 Mar 2013 Results presented at the 28th Congress of the European Association of Urology.